Value of pre-implantation genetic testing questioned

Dr Karin Hammarberg

writer

Dr Karin Hammarberg

Senior Research Fellow, Global and Women’s Health, School of Public Health & Preventive Medicine, Monash University

David Amor

writer

David Amor

Lorenzo and Pamela Galli Chair in Developmental Medicine, Murdoch Children’s Research Institute

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

If you’re going through IVF, you may be offered a test to look at your embryos’ chromosomes.

Pre-implantation genetic testing for aneuploidy (chromosome abnormalities), known as PGT-A, is an “add on” used to help choose embryos with the right number of chromosomes. It’s promoted by IVF clinics as a way to increase the chance of success, especially for women over 35.

But the evidence shows that in most cases, PGT-A doesn’t improve the chance of a baby.

What is aneuploidy?

Human cells usually contain 46 chromosomes. Aneuploidy is a term that describes a chromosome number that is different from 46 – either too many or too few chromosomes.

In human embryos, most aneuploidies are lethal, resulting in miscarriage, or do not result in pregnancy at all.

The chance of aneuploidy increases with the age of the woman; by the time a woman reaches age 40, approximately 80% of her embryos are aneuploid.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rod Baber

Prof Rod Baber

Menopausal Hormone Therapy - What Dose of Estrogen is Best?

Dr Adam Nelson

Dr Adam Nelson

Cardiovascular Benefits of GLP1s – New Evidence

Dr Kathleen McNamee, Prof Sonia Grover

Dr Kathleen McNamee, Prof Sonia Grover

Oral Contraceptive Pill in Teens

Prof Andrew Sindone

Prof Andrew Sindone

RSV and the Heart

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Karin Hammarberg

writer

Dr Karin Hammarberg

Senior Research Fellow, Global and Women’s Health, School of Public Health & Preventive Medicine, Monash University

David Amor

writer

David Amor

Lorenzo and Pamela Galli Chair in Developmental Medicine, Murdoch Children’s Research Institute

Test your knowledge

Recent articles

Latest GP poll

Do you believe the current authority prescription system should be:

Modified but kept in place

0%

Eliminated entirely without replacement

0%

Maintained as is

0%

Completely replaced with an alternative system

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease